A Phase 1b/2 Double-Blind Randomized Trial of the Hedgehog/SMO Antagonist LY2940680 in Combination with Carboplatin and Etoposide Followed by LY2940680 versus Carboplatin and Etoposide Plus Placebo Followed by Placebo in Patients with Extensive-Stage Small Cell Lung Cancer

ID Number 14-0453

Principal Investigator(s)
Jorge E Gomez

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this study is to evaluate the safety and effectiveness of an experimental drug called LY2940680. An experimental drug is not approved by the United States Food and Drug Administration (FDA) for use except in research studies. The study drug targets a protein in the cancer cells that may make the cancer cells more aggressive and make them spread faster.  The primary purpose of your participation in this study is to help answer the following research questions, and not to provide you treatment for your condition.

Phase 2:

Whether LY2940680 can help patients with small cell lung cancer.

How LY2940680 compares to placebo when given with carboplatin and etoposide.


Contact Information
(212) 824-7309

Recruiting Patients: No